ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Research Report 2025
Published Date: March 2025
|
Report Code: QYRE-Auto-4I10203
Home | Market Reports | Health| Pharmacy| Drugs & Medications
Global SERD Selective Estrogen Receptor Degrader Drugs Market Research Report 2022
BUY CHAPTERS

Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Research Report 2025

Code: QYRE-Auto-4I10203
Report
March 2025
Pages:88
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Amneal Pharmaceuticals, Inc.
Astrazeneca plc
Dr. Reddy’s Laboratories
Eli Lilly and Company
G1 Therapeutics Inc
Glenmark Pharmaceuticals
Hoffmann-La Roche AG
Novartis
Radius Health
Sanofi
Teva Pharmaceutical Industries Ltd
Zentalis Pharmaceuticals
HBT Labs, Inc
InventisBio
Zenopharm LLC.

SERD (Selective Estrogen Receptor Degrader) Drugs Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

SERD (Selective Estrogen Receptor Degrader) Drugs Market

SERD (Selective Estrogen Receptor Degrader) Drugs Market

The global market for SERD (Selective Estrogen Receptor Degrader) Drugs was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for SERD (Selective Estrogen Receptor Degrader) Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding SERD (Selective Estrogen Receptor Degrader) Drugs.
The SERD (Selective Estrogen Receptor Degrader) Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global SERD (Selective Estrogen Receptor Degrader) Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the SERD (Selective Estrogen Receptor Degrader) Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of SERD (Selective Estrogen Receptor Degrader) Drugs Market Report

Report Metric Details
Report Name SERD (Selective Estrogen Receptor Degrader) Drugs Market
CAGR 5%
Segment by Type
  • RAD1901
  • GDC-9545
  • AZD9833
  • SAR439859
  • Faslodex
  • Others
Segment by Application
  • First-Line Treatment
  • Second-Line Treatment
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Amneal Pharmaceuticals Inc, AstraZeneca, Plc., Dr. Reddy's Laboratories, Eli Lilly and Company, G1 Therapeutics, Inc., Glenmark Pharmaceuticals, HBT Labs, Inc, Hoffmann-La Roche AG, InventisBio, Novartis AG, Radius Health, Sanofi S.A., Teva Pharmaceutical Industries Ltd., Zenopharm LLC., Zentalis Pharmaceuticals
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of SERD (Selective Estrogen Receptor Degrader) Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the SERD (Selective Estrogen Receptor Degrader) Drugs Market report?

Ans: The main players in the SERD (Selective Estrogen Receptor Degrader) Drugs Market are Amneal Pharmaceuticals Inc, AstraZeneca, Plc., Dr. Reddy's Laboratories, Eli Lilly and Company, G1 Therapeutics, Inc., Glenmark Pharmaceuticals, HBT Labs, Inc, Hoffmann-La Roche AG, InventisBio, Novartis AG, Radius Health, Sanofi S.A., Teva Pharmaceutical Industries Ltd., Zenopharm LLC., Zentalis Pharmaceuticals

What are the Application segmentation covered in the SERD (Selective Estrogen Receptor Degrader) Drugs Market report?

Ans: The Applications covered in the SERD (Selective Estrogen Receptor Degrader) Drugs Market report are First-Line Treatment, Second-Line Treatment

What are the Type segmentation covered in the SERD (Selective Estrogen Receptor Degrader) Drugs Market report?

Ans: The Types covered in the SERD (Selective Estrogen Receptor Degrader) Drugs Market report are RAD1901, GDC-9545, AZD9833, SAR439859, Faslodex, Others

Recommended Reports

Hormone & Reproductive Drugs

Cancer & Targeted Therapy

Neurology & Others

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 RAD1901
1.2.3 GDC-9545
1.2.4 AZD9833
1.2.5 SAR439859
1.2.6 Faslodex
1.2.7 Others
1.3 Market by Application
1.3.1 Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 First-Line Treatment
1.3.3 Second-Line Treatment
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Perspective (2020-2031)
2.2 Global SERD (Selective Estrogen Receptor Degrader) Drugs Growth Trends by Region
2.2.1 Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 SERD (Selective Estrogen Receptor Degrader) Drugs Historic Market Size by Region (2020-2025)
2.2.3 SERD (Selective Estrogen Receptor Degrader) Drugs Forecasted Market Size by Region (2026-2031)
2.3 SERD (Selective Estrogen Receptor Degrader) Drugs Market Dynamics
2.3.1 SERD (Selective Estrogen Receptor Degrader) Drugs Industry Trends
2.3.2 SERD (Selective Estrogen Receptor Degrader) Drugs Market Drivers
2.3.3 SERD (Selective Estrogen Receptor Degrader) Drugs Market Challenges
2.3.4 SERD (Selective Estrogen Receptor Degrader) Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top SERD (Selective Estrogen Receptor Degrader) Drugs Players by Revenue
3.1.1 Global Top SERD (Selective Estrogen Receptor Degrader) Drugs Players by Revenue (2020-2025)
3.1.2 Global SERD (Selective Estrogen Receptor Degrader) Drugs Revenue Market Share by Players (2020-2025)
3.2 Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by SERD (Selective Estrogen Receptor Degrader) Drugs Revenue
3.4 Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Concentration Ratio
3.4.1 Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by SERD (Selective Estrogen Receptor Degrader) Drugs Revenue in 2024
3.5 Global Key Players of SERD (Selective Estrogen Receptor Degrader) Drugs Head office and Area Served
3.6 Global Key Players of SERD (Selective Estrogen Receptor Degrader) Drugs, Product and Application
3.7 Global Key Players of SERD (Selective Estrogen Receptor Degrader) Drugs, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 SERD (Selective Estrogen Receptor Degrader) Drugs Breakdown Data by Type
4.1 Global SERD (Selective Estrogen Receptor Degrader) Drugs Historic Market Size by Type (2020-2025)
4.2 Global SERD (Selective Estrogen Receptor Degrader) Drugs Forecasted Market Size by Type (2026-2031)
5 SERD (Selective Estrogen Receptor Degrader) Drugs Breakdown Data by Application
5.1 Global SERD (Selective Estrogen Receptor Degrader) Drugs Historic Market Size by Application (2020-2025)
5.2 Global SERD (Selective Estrogen Receptor Degrader) Drugs Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size (2020-2031)
6.2 North America SERD (Selective Estrogen Receptor Degrader) Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Country (2020-2025)
6.4 North America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe SERD (Selective Estrogen Receptor Degrader) Drugs Market Size (2020-2031)
7.2 Europe SERD (Selective Estrogen Receptor Degrader) Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Country (2020-2025)
7.4 Europe SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific SERD (Selective Estrogen Receptor Degrader) Drugs Market Size (2020-2031)
8.2 Asia-Pacific SERD (Selective Estrogen Receptor Degrader) Drugs Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Region (2020-2025)
8.4 Asia-Pacific SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size (2020-2031)
9.2 Latin America SERD (Selective Estrogen Receptor Degrader) Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Country (2020-2025)
9.4 Latin America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa SERD (Selective Estrogen Receptor Degrader) Drugs Market Size (2020-2031)
10.2 Middle East & Africa SERD (Selective Estrogen Receptor Degrader) Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Country (2020-2025)
10.4 Middle East & Africa SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Amneal Pharmaceuticals Inc
11.1.1 Amneal Pharmaceuticals Inc Company Details
11.1.2 Amneal Pharmaceuticals Inc Business Overview
11.1.3 Amneal Pharmaceuticals Inc SERD (Selective Estrogen Receptor Degrader) Drugs Introduction
11.1.4 Amneal Pharmaceuticals Inc Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2020-2025)
11.1.5 Amneal Pharmaceuticals Inc Recent Development
11.2 AstraZeneca, Plc.
11.2.1 AstraZeneca, Plc. Company Details
11.2.2 AstraZeneca, Plc. Business Overview
11.2.3 AstraZeneca, Plc. SERD (Selective Estrogen Receptor Degrader) Drugs Introduction
11.2.4 AstraZeneca, Plc. Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2020-2025)
11.2.5 AstraZeneca, Plc. Recent Development
11.3 Dr. Reddy's Laboratories
11.3.1 Dr. Reddy's Laboratories Company Details
11.3.2 Dr. Reddy's Laboratories Business Overview
11.3.3 Dr. Reddy's Laboratories SERD (Selective Estrogen Receptor Degrader) Drugs Introduction
11.3.4 Dr. Reddy's Laboratories Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2020-2025)
11.3.5 Dr. Reddy's Laboratories Recent Development
11.4 Eli Lilly and Company
11.4.1 Eli Lilly and Company Company Details
11.4.2 Eli Lilly and Company Business Overview
11.4.3 Eli Lilly and Company SERD (Selective Estrogen Receptor Degrader) Drugs Introduction
11.4.4 Eli Lilly and Company Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2020-2025)
11.4.5 Eli Lilly and Company Recent Development
11.5 G1 Therapeutics, Inc.
11.5.1 G1 Therapeutics, Inc. Company Details
11.5.2 G1 Therapeutics, Inc. Business Overview
11.5.3 G1 Therapeutics, Inc. SERD (Selective Estrogen Receptor Degrader) Drugs Introduction
11.5.4 G1 Therapeutics, Inc. Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2020-2025)
11.5.5 G1 Therapeutics, Inc. Recent Development
11.6 Glenmark Pharmaceuticals
11.6.1 Glenmark Pharmaceuticals Company Details
11.6.2 Glenmark Pharmaceuticals Business Overview
11.6.3 Glenmark Pharmaceuticals SERD (Selective Estrogen Receptor Degrader) Drugs Introduction
11.6.4 Glenmark Pharmaceuticals Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2020-2025)
11.6.5 Glenmark Pharmaceuticals Recent Development
11.7 HBT Labs, Inc
11.7.1 HBT Labs, Inc Company Details
11.7.2 HBT Labs, Inc Business Overview
11.7.3 HBT Labs, Inc SERD (Selective Estrogen Receptor Degrader) Drugs Introduction
11.7.4 HBT Labs, Inc Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2020-2025)
11.7.5 HBT Labs, Inc Recent Development
11.8 Hoffmann-La Roche AG
11.8.1 Hoffmann-La Roche AG Company Details
11.8.2 Hoffmann-La Roche AG Business Overview
11.8.3 Hoffmann-La Roche AG SERD (Selective Estrogen Receptor Degrader) Drugs Introduction
11.8.4 Hoffmann-La Roche AG Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2020-2025)
11.8.5 Hoffmann-La Roche AG Recent Development
11.9 InventisBio
11.9.1 InventisBio Company Details
11.9.2 InventisBio Business Overview
11.9.3 InventisBio SERD (Selective Estrogen Receptor Degrader) Drugs Introduction
11.9.4 InventisBio Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2020-2025)
11.9.5 InventisBio Recent Development
11.10 Novartis AG
11.10.1 Novartis AG Company Details
11.10.2 Novartis AG Business Overview
11.10.3 Novartis AG SERD (Selective Estrogen Receptor Degrader) Drugs Introduction
11.10.4 Novartis AG Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2020-2025)
11.10.5 Novartis AG Recent Development
11.11 Radius Health
11.11.1 Radius Health Company Details
11.11.2 Radius Health Business Overview
11.11.3 Radius Health SERD (Selective Estrogen Receptor Degrader) Drugs Introduction
11.11.4 Radius Health Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2020-2025)
11.11.5 Radius Health Recent Development
11.12 Sanofi S.A.
11.12.1 Sanofi S.A. Company Details
11.12.2 Sanofi S.A. Business Overview
11.12.3 Sanofi S.A. SERD (Selective Estrogen Receptor Degrader) Drugs Introduction
11.12.4 Sanofi S.A. Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2020-2025)
11.12.5 Sanofi S.A. Recent Development
11.13 Teva Pharmaceutical Industries Ltd.
11.13.1 Teva Pharmaceutical Industries Ltd. Company Details
11.13.2 Teva Pharmaceutical Industries Ltd. Business Overview
11.13.3 Teva Pharmaceutical Industries Ltd. SERD (Selective Estrogen Receptor Degrader) Drugs Introduction
11.13.4 Teva Pharmaceutical Industries Ltd. Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2020-2025)
11.13.5 Teva Pharmaceutical Industries Ltd. Recent Development
11.14 Zenopharm LLC.
11.14.1 Zenopharm LLC. Company Details
11.14.2 Zenopharm LLC. Business Overview
11.14.3 Zenopharm LLC. SERD (Selective Estrogen Receptor Degrader) Drugs Introduction
11.14.4 Zenopharm LLC. Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2020-2025)
11.14.5 Zenopharm LLC. Recent Development
11.15 Zentalis Pharmaceuticals
11.15.1 Zentalis Pharmaceuticals Company Details
11.15.2 Zentalis Pharmaceuticals Business Overview
11.15.3 Zentalis Pharmaceuticals SERD (Selective Estrogen Receptor Degrader) Drugs Introduction
11.15.4 Zentalis Pharmaceuticals Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2020-2025)
11.15.5 Zentalis Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
Amneal Pharmaceuticals, Inc.
Astrazeneca plc
Dr. Reddy’s Laboratories
Eli Lilly and Company
G1 Therapeutics Inc
Glenmark Pharmaceuticals
Hoffmann-La Roche AG
Novartis
Radius Health
Sanofi
Teva Pharmaceutical Industries Ltd
Zentalis Pharmaceuticals
HBT Labs, Inc
InventisBio
Zenopharm LLC.
List of Tables
 Table 1. Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of RAD1901
 Table 3. Key Players of GDC-9545
 Table 4. Key Players of AZD9833
 Table 5. Key Players of SAR439859
 Table 6. Key Players of Faslodex
 Table 7. Key Players of Others
 Table 8. Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 9. Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 10. Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Region (2020-2025) & (US$ Million)
 Table 11. Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Share by Region (2020-2025)
 Table 12. Global SERD (Selective Estrogen Receptor Degrader) Drugs Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 13. Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Share by Region (2026-2031)
 Table 14. SERD (Selective Estrogen Receptor Degrader) Drugs Market Trends
 Table 15. SERD (Selective Estrogen Receptor Degrader) Drugs Market Drivers
 Table 16. SERD (Selective Estrogen Receptor Degrader) Drugs Market Challenges
 Table 17. SERD (Selective Estrogen Receptor Degrader) Drugs Market Restraints
 Table 18. Global SERD (Selective Estrogen Receptor Degrader) Drugs Revenue by Players (2020-2025) & (US$ Million)
 Table 19. Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Share by Players (2020-2025)
 Table 20. Global Top SERD (Selective Estrogen Receptor Degrader) Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs as of 2024)
 Table 21. Ranking of Global Top SERD (Selective Estrogen Receptor Degrader) Drugs Companies by Revenue (US$ Million) in 2024
 Table 22. Global 5 Largest Players Market Share by SERD (Selective Estrogen Receptor Degrader) Drugs Revenue (CR5 and HHI) & (2020-2025)
 Table 23. Global Key Players of SERD (Selective Estrogen Receptor Degrader) Drugs, Headquarters and Area Served
 Table 24. Global Key Players of SERD (Selective Estrogen Receptor Degrader) Drugs, Product and Application
 Table 25. Global Key Players of SERD (Selective Estrogen Receptor Degrader) Drugs, Date of Enter into This Industry
 Table 26. Mergers & Acquisitions, Expansion Plans
 Table 27. Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Type (2020-2025) & (US$ Million)
 Table 28. Global SERD (Selective Estrogen Receptor Degrader) Drugs Revenue Market Share by Type (2020-2025)
 Table 29. Global SERD (Selective Estrogen Receptor Degrader) Drugs Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 30. Global SERD (Selective Estrogen Receptor Degrader) Drugs Revenue Market Share by Type (2026-2031)
 Table 31. Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Application (2020-2025) & (US$ Million)
 Table 32. Global SERD (Selective Estrogen Receptor Degrader) Drugs Revenue Market Share by Application (2020-2025)
 Table 33. Global SERD (Selective Estrogen Receptor Degrader) Drugs Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 34. Global SERD (Selective Estrogen Receptor Degrader) Drugs Revenue Market Share by Application (2026-2031)
 Table 35. North America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 36. North America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Country (2020-2025) & (US$ Million)
 Table 37. North America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Country (2026-2031) & (US$ Million)
 Table 38. Europe SERD (Selective Estrogen Receptor Degrader) Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 39. Europe SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Country (2020-2025) & (US$ Million)
 Table 40. Europe SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Country (2026-2031) & (US$ Million)
 Table 41. Asia-Pacific SERD (Selective Estrogen Receptor Degrader) Drugs Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 42. Asia-Pacific SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Region (2020-2025) & (US$ Million)
 Table 43. Asia-Pacific SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Region (2026-2031) & (US$ Million)
 Table 44. Latin America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 45. Latin America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Country (2020-2025) & (US$ Million)
 Table 46. Latin America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Country (2026-2031) & (US$ Million)
 Table 47. Middle East & Africa SERD (Selective Estrogen Receptor Degrader) Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 48. Middle East & Africa SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Country (2020-2025) & (US$ Million)
 Table 49. Middle East & Africa SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Country (2026-2031) & (US$ Million)
 Table 50. Amneal Pharmaceuticals Inc Company Details
 Table 51. Amneal Pharmaceuticals Inc Business Overview
 Table 52. Amneal Pharmaceuticals Inc SERD (Selective Estrogen Receptor Degrader) Drugs Product
 Table 53. Amneal Pharmaceuticals Inc Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2020-2025) & (US$ Million)
 Table 54. Amneal Pharmaceuticals Inc Recent Development
 Table 55. AstraZeneca, Plc. Company Details
 Table 56. AstraZeneca, Plc. Business Overview
 Table 57. AstraZeneca, Plc. SERD (Selective Estrogen Receptor Degrader) Drugs Product
 Table 58. AstraZeneca, Plc. Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2020-2025) & (US$ Million)
 Table 59. AstraZeneca, Plc. Recent Development
 Table 60. Dr. Reddy's Laboratories Company Details
 Table 61. Dr. Reddy's Laboratories Business Overview
 Table 62. Dr. Reddy's Laboratories SERD (Selective Estrogen Receptor Degrader) Drugs Product
 Table 63. Dr. Reddy's Laboratories Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2020-2025) & (US$ Million)
 Table 64. Dr. Reddy's Laboratories Recent Development
 Table 65. Eli Lilly and Company Company Details
 Table 66. Eli Lilly and Company Business Overview
 Table 67. Eli Lilly and Company SERD (Selective Estrogen Receptor Degrader) Drugs Product
 Table 68. Eli Lilly and Company Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2020-2025) & (US$ Million)
 Table 69. Eli Lilly and Company Recent Development
 Table 70. G1 Therapeutics, Inc. Company Details
 Table 71. G1 Therapeutics, Inc. Business Overview
 Table 72. G1 Therapeutics, Inc. SERD (Selective Estrogen Receptor Degrader) Drugs Product
 Table 73. G1 Therapeutics, Inc. Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2020-2025) & (US$ Million)
 Table 74. G1 Therapeutics, Inc. Recent Development
 Table 75. Glenmark Pharmaceuticals Company Details
 Table 76. Glenmark Pharmaceuticals Business Overview
 Table 77. Glenmark Pharmaceuticals SERD (Selective Estrogen Receptor Degrader) Drugs Product
 Table 78. Glenmark Pharmaceuticals Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2020-2025) & (US$ Million)
 Table 79. Glenmark Pharmaceuticals Recent Development
 Table 80. HBT Labs, Inc Company Details
 Table 81. HBT Labs, Inc Business Overview
 Table 82. HBT Labs, Inc SERD (Selective Estrogen Receptor Degrader) Drugs Product
 Table 83. HBT Labs, Inc Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2020-2025) & (US$ Million)
 Table 84. HBT Labs, Inc Recent Development
 Table 85. Hoffmann-La Roche AG Company Details
 Table 86. Hoffmann-La Roche AG Business Overview
 Table 87. Hoffmann-La Roche AG SERD (Selective Estrogen Receptor Degrader) Drugs Product
 Table 88. Hoffmann-La Roche AG Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2020-2025) & (US$ Million)
 Table 89. Hoffmann-La Roche AG Recent Development
 Table 90. InventisBio Company Details
 Table 91. InventisBio Business Overview
 Table 92. InventisBio SERD (Selective Estrogen Receptor Degrader) Drugs Product
 Table 93. InventisBio Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2020-2025) & (US$ Million)
 Table 94. InventisBio Recent Development
 Table 95. Novartis AG Company Details
 Table 96. Novartis AG Business Overview
 Table 97. Novartis AG SERD (Selective Estrogen Receptor Degrader) Drugs Product
 Table 98. Novartis AG Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2020-2025) & (US$ Million)
 Table 99. Novartis AG Recent Development
 Table 100. Radius Health Company Details
 Table 101. Radius Health Business Overview
 Table 102. Radius Health SERD (Selective Estrogen Receptor Degrader) Drugs Product
 Table 103. Radius Health Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2020-2025) & (US$ Million)
 Table 104. Radius Health Recent Development
 Table 105. Sanofi S.A. Company Details
 Table 106. Sanofi S.A. Business Overview
 Table 107. Sanofi S.A. SERD (Selective Estrogen Receptor Degrader) Drugs Product
 Table 108. Sanofi S.A. Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2020-2025) & (US$ Million)
 Table 109. Sanofi S.A. Recent Development
 Table 110. Teva Pharmaceutical Industries Ltd. Company Details
 Table 111. Teva Pharmaceutical Industries Ltd. Business Overview
 Table 112. Teva Pharmaceutical Industries Ltd. SERD (Selective Estrogen Receptor Degrader) Drugs Product
 Table 113. Teva Pharmaceutical Industries Ltd. Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2020-2025) & (US$ Million)
 Table 114. Teva Pharmaceutical Industries Ltd. Recent Development
 Table 115. Zenopharm LLC. Company Details
 Table 116. Zenopharm LLC. Business Overview
 Table 117. Zenopharm LLC. SERD (Selective Estrogen Receptor Degrader) Drugs Product
 Table 118. Zenopharm LLC. Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2020-2025) & (US$ Million)
 Table 119. Zenopharm LLC. Recent Development
 Table 120. Zentalis Pharmaceuticals Company Details
 Table 121. Zentalis Pharmaceuticals Business Overview
 Table 122. Zentalis Pharmaceuticals SERD (Selective Estrogen Receptor Degrader) Drugs Product
 Table 123. Zentalis Pharmaceuticals Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2020-2025) & (US$ Million)
 Table 124. Zentalis Pharmaceuticals Recent Development
 Table 125. Research Programs/Design for This Report
 Table 126. Key Data Information from Secondary Sources
 Table 127. Key Data Information from Primary Sources
 Table 128. Authors List of This Report


List of Figures
 Figure 1. SERD (Selective Estrogen Receptor Degrader) Drugs Picture
 Figure 2. Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Share by Type: 2024 VS 2031
 Figure 4. RAD1901 Features
 Figure 5. GDC-9545 Features
 Figure 6. AZD9833 Features
 Figure 7. SAR439859 Features
 Figure 8. Faslodex Features
 Figure 9. Others Features
 Figure 10. Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Application (2020-2031) & (US$ Million)
 Figure 11. Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Share by Application: 2024 VS 2031
 Figure 12. First-Line Treatment Case Studies
 Figure 13. Second-Line Treatment Case Studies
 Figure 14. SERD (Selective Estrogen Receptor Degrader) Drugs Report Years Considered
 Figure 15. Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 16. Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 17. Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Share by Region: 2024 VS 2031
 Figure 18. Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Share by Players in 2024
 Figure 19. Global Top SERD (Selective Estrogen Receptor Degrader) Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs as of 2024)
 Figure 20. The Top 10 and 5 Players Market Share by SERD (Selective Estrogen Receptor Degrader) Drugs Revenue in 2024
 Figure 21. North America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 22. North America SERD (Selective Estrogen Receptor Degrader) Drugs Market Share by Country (2020-2031)
 Figure 23. United States SERD (Selective Estrogen Receptor Degrader) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 24. Canada SERD (Selective Estrogen Receptor Degrader) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 25. Europe SERD (Selective Estrogen Receptor Degrader) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 26. Europe SERD (Selective Estrogen Receptor Degrader) Drugs Market Share by Country (2020-2031)
 Figure 27. Germany SERD (Selective Estrogen Receptor Degrader) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 28. France SERD (Selective Estrogen Receptor Degrader) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. U.K. SERD (Selective Estrogen Receptor Degrader) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. Italy SERD (Selective Estrogen Receptor Degrader) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 31. Russia SERD (Selective Estrogen Receptor Degrader) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 32. Nordic Countries SERD (Selective Estrogen Receptor Degrader) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 33. Asia-Pacific SERD (Selective Estrogen Receptor Degrader) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 34. Asia-Pacific SERD (Selective Estrogen Receptor Degrader) Drugs Market Share by Region (2020-2031)
 Figure 35. China SERD (Selective Estrogen Receptor Degrader) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 36. Japan SERD (Selective Estrogen Receptor Degrader) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. South Korea SERD (Selective Estrogen Receptor Degrader) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. Southeast Asia SERD (Selective Estrogen Receptor Degrader) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 39. India SERD (Selective Estrogen Receptor Degrader) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 40. Australia SERD (Selective Estrogen Receptor Degrader) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 41. Latin America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 42. Latin America SERD (Selective Estrogen Receptor Degrader) Drugs Market Share by Country (2020-2031)
 Figure 43. Mexico SERD (Selective Estrogen Receptor Degrader) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 44. Brazil SERD (Selective Estrogen Receptor Degrader) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 45. Middle East & Africa SERD (Selective Estrogen Receptor Degrader) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 46. Middle East & Africa SERD (Selective Estrogen Receptor Degrader) Drugs Market Share by Country (2020-2031)
 Figure 47. Turkey SERD (Selective Estrogen Receptor Degrader) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 48. Saudi Arabia SERD (Selective Estrogen Receptor Degrader) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 49. UAE SERD (Selective Estrogen Receptor Degrader) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 50. Amneal Pharmaceuticals Inc Revenue Growth Rate in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2020-2025)
 Figure 51. AstraZeneca, Plc. Revenue Growth Rate in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2020-2025)
 Figure 52. Dr. Reddy's Laboratories Revenue Growth Rate in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2020-2025)
 Figure 53. Eli Lilly and Company Revenue Growth Rate in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2020-2025)
 Figure 54. G1 Therapeutics, Inc. Revenue Growth Rate in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2020-2025)
 Figure 55. Glenmark Pharmaceuticals Revenue Growth Rate in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2020-2025)
 Figure 56. HBT Labs, Inc Revenue Growth Rate in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2020-2025)
 Figure 57. Hoffmann-La Roche AG Revenue Growth Rate in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2020-2025)
 Figure 58. InventisBio Revenue Growth Rate in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2020-2025)
 Figure 59. Novartis AG Revenue Growth Rate in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2020-2025)
 Figure 60. Radius Health Revenue Growth Rate in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2020-2025)
 Figure 61. Sanofi S.A. Revenue Growth Rate in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2020-2025)
 Figure 62. Teva Pharmaceutical Industries Ltd. Revenue Growth Rate in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2020-2025)
 Figure 63. Zenopharm LLC. Revenue Growth Rate in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2020-2025)
 Figure 64. Zentalis Pharmaceuticals Revenue Growth Rate in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2020-2025)
 Figure 65. Bottom-up and Top-down Approaches for This Report
 Figure 66. Data Triangulation
 Figure 67. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Novocure

SIMILAR REPORTS

Estrogen Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Selective Estrogen Receptor Degrader Market Research Report 2024
Global ER Targeted Drugs for Breast Cancer Market Research Report 2024
Woman Disease Pharmaceutical Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Endocrine Therapy Drugs for Breast Cancer Market Research Report 2024
Menopause Hormonal Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Rare Endocrine Disorders Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Menopause Hormonal Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Major Depressive Disorder Drug Market Research Report 2025
Antidepressants Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Assisted Reproductive Technology Drugs Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Assisted Reproduction Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Antidepressant Medication Market Research Report 2025
Drugs for HR HER2 Advanced Breast Cancer Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Depression MDD Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Adrenogenital Syndrome Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Breast Cancer Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Targeted Drugs for Breast Cancer Market Research Report 2024
Global Autoimmune Diseases Treatment Market Research Report 2024
Global Female Contraception Drug Market Research Report 2024

RELATED REPORTS

Global Long-Acting HIV-1 Inhibitors Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-19B19893
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Methylphenidate Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-30B3636
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Soliris Intravenous Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-3H1702
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Mouth Ulcers Drugs Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-13C3384
Wed Sep 10 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions